Last reviewed · How we verify
NCT00568880
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 trial testing bortezomib in Multiple Myeloma and Plasma Cell Neoplasm in 25 participants. Completed in 22 June 2011.
22 June 2011
Quick facts
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 8 September 2010 |
| Primary completion | 22 June 2011 |
| Estimated completion | 22 June 2011 |
| Sites | 1 location across United States |
Drugs / interventions tested
- bortezomib (bortezomib) — full drug profile →
- hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Conditions studied
- Multiple Myeloma and Plasma Cell Neoplasm — all drugs for Multiple Myeloma and Plasma Cell Neoplasm →
Sponsor
Abramson Cancer Center at Penn Medicine — full company profile →
Who can join
Adults 18 to 120, any sex, with Multiple Myeloma and Plasma Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with bortezomib may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of hydroxychloroquine when given together with bortezomib and to see how well it works in treating patients with relapsed or refractory multiple myeloma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment.
Sui X, Chen R, Wang Z, Huang Z, et al · · 2013 · cited 940× · PMID 24113172 · DOI 10.1038/cddis.2013.350 -
The double-edged sword of autophagy modulation in cancer.
White E, DiPaola RS. · · 2009 · cited 902× · PMID 19706824 · DOI 10.1158/1078-0432.ccr-07-5023 -
Principles and current strategies for targeting autophagy for cancer treatment.
Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, et al · · 2011 · cited 707× · PMID 21325294 · DOI 10.1158/1078-0432.ccr-10-2634 -
Autophagy and human diseases.
Jiang P, Mizushima N. · · 2014 · cited 611× · PMID 24323045 · DOI 10.1038/cr.2013.161 -
Role and regulation of autophagy in cancer.
Chen N, Karantza-Wadsworth V. · · 2009 · cited 280× · PMID 19167434 · DOI 10.1016/j.bbamcr.2008.12.013 -
Autophagy as a therapeutic target in cancer.
Chen N, Karantza V. · · 2011 · cited 245× · PMID 21228626 · DOI 10.4161/cbt.11.2.14622 -
Role of lysosomes in physiological activities, diseases, and therapy.
Zhang Z, Yue P, Lu T, Wang Y, et al · · 2021 · cited 238× · PMID 33990205 · DOI 10.1186/s13045-021-01087-1 -
Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.
Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, et al · · 2017 · cited 198× · PMID 29225688 · DOI 10.3332/ecancer.2017.781
Verify or expand the search:
- PubMed search for NCT00568880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of bortezomib
Trials testing the same drug.
- NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
- NCT06140966 — Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera · Phase 2 · recruiting
- NCT03641456 — VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma · Phase 2 · unknown
- NCT02976272 — Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple · unknown
- NCT02513186 — Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + De · Phase 1 · completed
Other recruiting trials for Multiple Myeloma and Plasma Cell Neoplasm
Currently open trials in the same condition.
- NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders · Phase 2 · active not recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
- NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
- NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00568880 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
- Last refreshed: 7 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00568880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing